Metabolic Syndrome is a clustering of cardiovascular risk factors. It is highly prevalent with approximately 20-25% of adults affected. It is estimated that having Metabolic Syndrome leads to a person being three times more likely to have a stroke or heart attack and five times more likely to develop diabetes. However, the pathophysiological processes leading to Metabolic Syndrome remain unclear, with no universally accepted definition. The IDF (International Diabetes Federation) has proposed a metabolic syndrome definition for worldwide application. They propose that a person must have central obesity plus two of the following:
- Raised triglycerides
- Reduced HDL cholesterol
- Raised blood pressure
- Raised fasting plasma glucose
Metabolic Syndrome Array I
• C-peptide
• Ferritin
• Interleukin-1α (IL-1α)
• Interleukin-6 (IL-6)
• Insulin
• Leptin
• Plasminogen Activator Inhibitor-1 (PAI-1)
• Resistin
• Tumour Necrosis Factor α (TNFα)

Metabolic Syndrome Array II
• Adiponectin
• C-reactive Protein (CRP)
• Cystatin C
Key Benefits
• Multiple assays from one sample using Biochip Array Technology
• Analytes have been carefully selected for application to a wide range of clinical research studies
• Suitable for both serum and plasma samples
• Small sample volume - 100 μl to measure all analytes on each array
• Very efficient use of highly valuable patient sample banks
• Quick time to results
• Multi-analyte controls and calibrators available
• Excellent assay performance
• Range of associated arrays available for comprehensive studies
• No none-specific aggregation associated with multi-analyte bead assays